The Cooperative Research Centre for Cell Therapy Manufacturing (CTM CRC), GE Healthcare Australia (GE Healthcare) and Health Industries South Australia have signed a strategic cooperation agreement that will lay the foundation for a long term partnership focussed on advancing Australia’s cell therapy industry.
The agreement outlines the three parties’ plans to work together to further develop their relationships, improve industry networks, and leverage the strengths of each organisation to address industry challenges and deliver novel cell therapy solutions.
Michael Ackland, CEO & President of GE Healthcare A&NZ views this as a long term partnership which will see South Australia become an important hub for healthcare delivery and a vital link for cell therapy innovation.
“We are delighted this agreement has been signed, having the Cooperative Research Centre for Cell Therapy Manufacturing and Health Industries South Australia partner with us means that together we can leverage our unique expertise and skills, develop key relationships and deliver on ground-breaking work.”
CTM CRC, GE Healthcare and Health Industries SA each share a vision to drive healthcare improvements through the delivery of cell-based therapeutics. Specific areas for collaboration identified in the agreement include, process development and cell therapy manufacturing infrastructure design and supply, engagement models for multi-disciplinary research & development initiatives, access to industry partners and global networks, investment, funding support and training.
Dr Sherry Kothari, CEO, CTM CRC said the cooperation agreement was an important step in meeting industry challenges and delivering cost-effective cell therapies.
“This is an exciting development that will strengthen our overall capability and enable the translation of new technologies into cell therapy manufacturing tools and processes. CTM CRC has a strong focus on using smart materials technologies to introduce efficiencies and reduce the cost of goods involved in cell therapy manufacturing. Leveraging GE Healthcare’s experience and know-how in process development and manufacturing infrastructure will enhance CTM CRC’s delivery of integrated solutions for this rapidly growing industry,” Dr Kothari said.
South Australian Minister for Health Industries, the Hon Jack Snelling welcomed the collaboration.
“The field of cell therapy has been recognised by the South Australian government as an area with the potential to improve healthcare outcomes and drive economic growth for the region,” Mr Snelling said.
“South Australia is establishing itself as a global biomedical leader by constructing the $3 billion South Australian Biomedical Precinct, which when complete will be the largest health and biomedical precinct in the Southern Hemisphere with state-of-the-art facilities, world-class research and a new hospital.”
The Chief Executive Officer of Health Industries SA, Marco Baccanti, outlined the advantages for South Australia from the arrangement: “The complementary capabilities and assets encompassed within CTM CRC and this precinct will competitively position South Australia for the development and growth of a cell therapy industry for Australia and the Asia Pacific region”.
“The agreement between a global engineering leader such as GE Healthcare and CTM CRC, endorsed by the Government of South Australia through Health Industries SA, represents a unique combination of multi-stakeholder commitment and expertise,” Mr Baccanti said.
The platform is now available for global pharmaceutical and biotechnology companies to access the facility, engineering experience and know how offered by CTM CRC and GE Healthcare and the endorsement and incentives offered by the Government of South Australia to accelerate the research and the scale up of cell therapies.
Click here for media release